Alzheimer's Disease and Parkinson's Disease
Open accessThe DOI matches its Crossref record; 106 of the 107 references it cites were found in a registry or an index.
Abstract
Although most cases of Alzheimer's and Parkinson's disease are sporadic, some cases are clearly familial. This review, part of the Genomic Medicine series, examines the genetics of these familial forms. Although the inherited forms are rare, the knowledge derived from investigating their pathobiology has improved our understanding of the pathobiology of the more common, sporadic forms of the diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In general terms, neurodegenerative diseases are thought to be driven by the accumulation of neurotoxic material such as amyloid beta (Aβ) or myelin debris in the central nervous system (CNS) (Nussbaum and Ellis, 2003; Trapp and Nave, 2008).”
From SYK coordinates neuroprotective microglial responses in neurodegenerative disease (2022) · cites this paper as Nussbaum and Ellis, 2003
In the citing paper
“PD pathology is mainly characterized by loss of neurons from the substantia nigra pars compacta in association with the accumulation of ubiquitinated alpha synuclein and other proteins in cytoplasmic inclusions (Lewy bodies) and thread-like proteinaceous inclusions within neurites (Lewy neuritis).”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [4]
In the citing paper
“However, Lewy bodies are also seen in the cerebral cortex, brainstem nuclei, limbic system, sympathetic ganglia, nucleus basalis of Meinert and myenteric plexus [4].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [4]
In the citing paper
“This review is focused on the potential of herbal medicine in AD since it is responsible for more than two-thirds of all dementia cases [5,6].”
From Indian Medicinal Herbs and Formulations for Alzheimer’s Disease, from Traditional Knowledge to Scientific Assessment (2020) · cites this paper as [6]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378 · cited 4×
“Increased Abeta42(43) from cell lines expressing presenilin 1 mutations.”
BackgroundInfluentialSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Self-citationMutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Research works printed but not linked: 5
- 10.1001/archinte.151.5.989 · doi:10.1001/archinte.151.5.989 · Paper page
- Clark CM, Ewbank D, Lee VM-Y, Trojanowski JQ. Molecular pathology of Alzheimer's disease: neuronal cytoskeletal abnormalities. In: Growdon JH, Rossor MN, eds. The dementias. Vol. 19 of Blue books of practical neurology. Boston: Butterworth–Heinemann, 1998:285-304.
- Duvoisin RC, 1996, Adv Neurol, 69, 33
- Louis ED, 1996, Adv Neurol, 69, 311
- Matsumine H, 1997, Am J Hum Genet, 60, 588
Cited by
Items 801–900 of 1,000
Zheng, Y., Zhou, J. M., Wang, Y., Fan, F., Liu, S., & Wang, Y. (2022) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szac006 · Cited by 14
Neirinckx, V., Coste, C., Rogister, B., & Wislet‐Gendebien, S. (2013) · InTech eBooks · doi:10.5772/53260 · Cited by 14
Yoshikawa, T., Zhang, Z., Yamashita, K., & Noda, M. (2016) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2016.04.185 · Cited by 12
Removable prosthesis hygiene in elders with Parkinson's disease
Ribeiro, G. R., Campos, C. H., & Garcia, R. C. M. R. (2017) · Special Care in Dentistry · doi:10.1111/scd.12251 · Cited by 12
“J Int Soc Prev Community Dent 2014;4(3):145-48.”
BackgroundInfluentialKlietz, M., Öcalan, Ö., Schneider, N., Dressler, D. W., Stiel, S., & Wegner, F. (2019) · Parkinson s Disease · doi:10.1155/2019/2107821 · Cited by 12
“Parkinson’s disease (PD) is the second most common neurodegenerative disease worldwide [1] with an estimated increase in prevalence during the next decades due to demographic change [2].”
Herbal Medicines as a Rational Alternative for Treatment of Human Diseases
Chaudhari, A. K., Das, S., Singh, B. K., Prasad, J., Dubey, N. K., & Dwivedy, A. K. (2020) · Springer eBooks · doi:10.1007/978-981-15-5917-4_2 · Cited by 16
Detecting placebo and drug effects on Parkinson's disease symptoms by longitudinal item‐score models
Chen, C., Jönsson, S., Yang, S., Plan, E. L., & Karlsson, M. O. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12601 · Cited by 12
King, G., Veros, K. M., MacLaren, D. A. A., Leigh, M. P. K., Spernyak, J. A., & Clark, S. D. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15496 · Cited by 12
Kashihara, Y., Terao, Y., Yoda, K., Hirota, T., Kubota, T., Kimura, M., Matsuki, S., Hirakawa, M., Irie, S., & Ieiri, I. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2568-4 · Cited by 12
Development and Characterization of a TAPIR-Like Mouse Monoclonal Antibody to Amyloid-β
Wang, J., Hara, H., Makifuchi, T., & Tabira, T. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14204 · Cited by 12
Miao, H., Yu, L., Hui, G., & Guo, L. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00002.x · Cited by 12
Imaging Markers in Genetic Forms of Parkinson’s Disease
Droby, A., Thaler, A., & Mirelman, A. (2023) · Brain Sciences · doi:10.3390/brainsci13081212 · Cited by 12
“3% of the overall population, reaching 1% in individuals above 60 years of age [2].”
BackgroundAllami, P., Yazdanpanah, N., & Rezaei, N. (2025) · Reviews in the Neurosciences · doi:10.1515/revneuro-2024-0153 · Cited by 12
[Cerebrospinal fluid biomarkers for the early diagnosis of Parkinson's disease].
Costa, A., Gago, M. F., & Garrett, C. (2011) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.20344/amp.1596 · Cited by 12
Lee, J. Y., Lim, N. G., Chung, C. K., Lee, J., Kim, H. J., & Park, S. B. (2019) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2018.0012 · Cited by 11
Aminabad, E. D., Hasanzadeh, M., Ahmadalipour, A., Mahmoudi, T., Feizi, M. A. H., Safaralizadeh, R., & Mobed, A. (2022) · Journal of Molecular Recognition · doi:10.1002/jmr.2952 · Cited by 11
Insights Into the Role of Heat Shock Protein 27 in the Development of Neurodegeneration
Holguin, B. A., Hildenbrand, Z. L., & Bernal, R. A. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.868089 · Cited by 13
Liang, W., Yao, L., Chen, J., Chen, Z., Wu, X., & Huang, X. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/9191284 · Cited by 11
“Introduction Parkinson’s disease (PD) is a progressive neurodegenerative movement disorder, with an incidence of approximately 1% in the population over 60 years of age [1].”
BackgroundEstablishing the Correlation between Parkinson's and Heart Disease using Machine Learning Algorithm
Kumar, N., Avasthi, S., & Prakash, A. (2023) · International Conference on Computational Intelligence, Communication Technology and Networking (CICTN) · doi:10.1109/cictn57981.2023.10141225 · Cited by 11
Multi-omics analysis reveals the genetic aging landscape of Parkinson’s disease
Wang, Z., Zhang, Z., Li, P., Cao, Q., Fan, P., Xia, H., & Yang, X. (2024) · Scientific Reports · doi:10.1038/s41598-024-82470-z · Cited by 13
Sohgawa, M., Zhang, Z., Akai, T., Takada, K., Yamashita, K., & Noda, M. (2015) · IEEE Sensors Journal · doi:10.1109/jsen.2015.2470108 · Cited by 11
“Amyloid beta (Aβ) proteins is considered as a major causative agent of Alzheimer’s diseases because they aggregate and deposit on surface of brain cells [2], [3].”
BackgroundDelunardo, F., Margutti, P., Pontecorvo, S., Colasanti, T., Conti, F., Riganò, R., Profumo, E., Siracusano, A., Capozzi, A., Prencipe, M., et al. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2007.09.027 · Cited by 14
“A limit of this study is that the clinical diagnosis of AD is not completely definite and is made by exclusion of other dementing diseases; a definite diagnosis can only be made at autopsy (Nussbaum and Ellis, 2003).”
BackgroundAnti-Chol-1 Antigen, GQ1bα, Antibodies Are Associated with Alzheimer’s Disease
Ariga, T., Kubota, M., Nakane, M., Oguro, K., Yu, R. K., & Ando, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063326 · Cited by 11
“The disease also affects more women than men [1,2,3].”
BackgroundIikuni, S., Ono, M., Tanimura, K., Watanabe, H., Yoshimura, M., & Saji, H. (2017) · RSC Advances · doi:10.1039/c6ra28395k · Cited by 11
MacLaren, D. A. A., Ljungberg, T. L., Griffin, M. E., & Clark, S. D. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14212 · Cited by 11
Gupta, A. K., Kumar, G. K., Rani, K., Pokhriyal, R., Khan, M. I., Kumar, D. R., Goyal, V., Tripathi, M., Gupta, R., Chadda, R. K., et al. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s198559 · Cited by 11
Possible Role of Amyloid Cross-Seeding in Evolvability and Neurodegenerative Disease
Hashimoto, M., Ho, G. J., Takamatsu, Y., Wada, R., Sugama, S., Takenouchi, T., Waragai, M., & Masliah, E. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-191675 · Cited by 11
“For instance, aggregation of -synuclein ( S) is thought to be upstream of other neuropathological features leading to the disease manifestation in PD [4].”
BackgroundMutation analysis of LRP10 in a large Chinese familial Parkinson disease cohort
Li, C., Chen, Y., Ou, R., Gu, X., Wei, Q., Cao, B., Zhang, L., Hou, Y., Liu, K., Chen, X., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.08.015 · Cited by 11
Thieken, F., Timmermann, L., Sohrabi, K., Woopen, C., Schmitz‐Luhn, B., Janhsen, A., & Eggers, C. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-202391 · Cited by 11
“Parkinson’s disease (PD) is one of the most common neurodegenerative disorders [2] and can be an extremely hefty burden for patients, families, and caregivers.”
Parveen, Z., Nawaz, M. S., Shakil, S., Greig, N. H., & Kamal, M. A. (2012) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152712800792884 · Cited by 11
Vila‐Chã, N., Cavaco, S., Mendes, A., Gonçalves, A., Moreira, I. C., Fernandes, J., Damásio, J., Azevedo, L. F., & Castro‐Lopes, J. M. (2019) · European Journal of Pain · doi:10.1002/ejp.1413 · Cited by 12
“PD is the second most common neurodegenerative disease (Nussbaum & Ellis, 2003) and has been classically described as a disease with motor symptoms, such as bradykinesia, tremor at rest, rigidity and postural instability (Herzberg, 1990).”
BackgroundParkin Attenuates Wild-Type τ Modification in the Presence of β-Amyloid and α-Synuclein
Moussa, C. (2009) · Journal of Molecular Neuroscience · doi:10.1007/s12031-008-9167-2 · Cited by 11
Padovani, A., Gilberti, N., & Borroni, B. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/296374 · Cited by 11
Impaired astrocytic synaptic function by peripheral cholesterol metabolite 27-hydroxycholesterol
Spanos, F., Gerenu, G., Goikolea, J., Latorre-Leal, M., Balleza-Tapia, H., Gomez, K., Álvarez-Jiménez, L., Piras, A., Gómez-Galán, M., Fisahn, A., et al. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1347535 · Cited by 10
Alo, B., & Lamers, C. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00153 · Cited by 11
Kim, Y.-E., Cho, H., Kim, H. J., Na, D. L., Seo, S. W., & Ki, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-59829-z · Cited by 10
Gut Microbiota Dynamics in Parkinsonian Mice
Klann, E. M., Tagliamonte, M. S., Ukhanova, M., Mai, V., & Vedam‐Mai, V. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00386 · Cited by 10
Warerkar, O. D., Mudliar, N. H., Ahuja, T., Shahane, S. D., & Singh, P. K. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.125621 · Cited by 11
Yi, Z., Mao, Y., He, C., Zhang, Y., Zhou, J., & Feng, X. L. (2024) · BMC Public Health · doi:10.1186/s12889-024-18431-y · Cited by 11
Li, Z., Cui, M., Zhang, J., Dai, J., Zhang, X., Peng, C., Jia, H., & Liu, B. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.07.070 · Cited by 10
Saqlain, M., Alam, M., Rönnegård, L., & Westin, J. (2019) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-019-00580-w · Cited by 10
Yang, S., Zhou, F., Ma, M., Yuan, Y., Zhao, S., & Yu, P. (2020) · Neurochemical Research · doi:10.1007/s11064-020-03106-y · Cited by 11
[Genetic factors associated with dementia in Parkinson's disease (PD)].
Romo-Gutiérrez, D., Yescas, P., López, M., & Boll, M. (2015) · PubMed · Cited by 10
Díaz, M., Vaamonde, L., & Dajas, F. (2015) · General Medicine Open Access · doi:10.4172/2327-5146.1000207 · Cited by 20
Demographic study of parkinson's disease in Iran: Data on 1656 cases.
Mohammad, R., Shahidi, G. A., & Miri, S. (2011) · PubMed Central · Cited by 10
Qiang, T., Gai, C., Chai, Y., Feng, W.-D., Ma, H., Zhang, Y., Feng, J., Guo, Z., Ma, L., & Sun, H. (2019) · Journal of Traditional Chinese Medical Sciences · doi:10.1016/j.jtcms.2019.01.005 · Cited by 10
Assessing Retinal Structure in Patients with Parkinson Disease
Young, J. B., Godara, P., Williams, V. V., Summerfelt, P., Connor, T. B., Tarima, S. S., Visotcky, A. M., Cooper, R. F., Blindauer, K. A., & Carroll, J. (2019) · Journal of Neurology & Neurophysiology · doi:10.4172/2155-9562.1000485 · Cited by 10
Huang, T., Gao, C., Wu, L., Gong, P., Wang, J., Tian, Y., & Zhang, Y. (2019) · Brain and Behavior · doi:10.1002/brb3.1372 · Cited by 10
“The incidence of PD increases with age, affecting greater than 1% of the population over the age of 60 and greater than 4% of the population over the age of 80 (Nussbaum & Ellis, 2003).”
BackgroundWimalarathne, D. N., Ruan, W., Sun, X., Liu, F., Gai, Y., Liu, Q., Hu, F., & Lan, X. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.823292 · Cited by 11
“AD is caused due to abnormal build-up of amyloid and tau proteins in and around the neurons which disrupt the function of the neurons by triggering the neuronal damage or eventually dead cells, particularly in the cortex and hippocampus, whereas PD affects predominantly dopaminergic neurons in a specific area in the b…”
BackgroundCochlear Implantation in a Patient With Bilateral Deep Brain Stimulators
Martin, M. B. S., & Hirsch, B. E. (2006) · The Laryngoscope · doi:10.1097/01.mlg.0000245943.95695.65 · Cited by 10
Galantamine Extended Release in Alzheimer??s Disease1: Profile Report
Robinson, D. M., & Plosker, G. L. (2006) · Drugs & Aging · doi:10.2165/00002512-200623100-00006 · Cited by 10
Lee, J. H., Byeon, S. R., Lim, S. J., Oh, S. J., Moon, D. H., Yoo, K. H., Chung, B. Y., & Kim, D. J. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.10.004 · Cited by 16
Biomedicine and Informatics Model of Alzheimer’s disease
., K. C., & Zou, C. (2007) · American journal of biochemistry & biotechnology/American journal of biochemistry and biotechnology · doi:10.3844/ajbbsp.2007.145.149 · Cited by 12
The Primary Care of Alzheimer Disease
Rubin, C. D. (2006) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200612000-00004 · Cited by 13
“Cochrane Database Syst Rev 2000;(4):CD002854.”
ResultWesseling, C., Román, N., Quirós, I., Páez, L., García, V., María Mora, A., Juncos, J. L., & Steenland, K. N. (2013) · Global Health Action · doi:10.3402/gha.v6i0.23061 · Cited by 9
An Overview of Transgenic Mouse Models for the Study of Alzheimer’s Disease
Lopes, P. A., Pádua, M. S., & Guil‐Guerrero, J. L. (2025) · Journal of dementia and Alzheimer's disease · doi:10.3390/jdad2010002 · Cited by 10
“Alzheimer’s disease (AD), the leading cause of dementia worldwide, is a neurological multifactorial and multigenetic disease characterised by a complex interplay of factors that lead to synaptic damage and neuron loss, predominantly affecting the cortex and the hippocampus [9,10].”
Qarin, S., Howlett, S., Jones, J., & Barker, R. A. (2021) · Neuronal Signaling · doi:10.1042/ns20200083 · Cited by 9
Lipid-lowering drug targets and Parkinson's disease: A sex-specific Mendelian randomization study
Zhao, Y., & Taliun, S. A. G. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.940118 · Cited by 9
“Late-onset Parkinson’s disease (PD) is a multifactorial neurodegenerative disorder that affects millions of individuals worldwide (1, 2).”
BackgroundThe risk of Parkinson’s disease in diabetic people: an updated systematic review and meta-analysis
Azami, M., Moradkhani, A., Afraie, M., Khateri, S., Sharifian, E., Zamani, K., & Moradi, Y. (2023) · Acta Neurologica Belgica · doi:10.1007/s13760-023-02424-6 · Cited by 9
Salaramoli, S., Joshaghani, H., Shoeibi, A., & Hashemy, S. I. (2023) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2023.127344 · Cited by 9
The Prevalence of Parkinson’s Disease in Poland: Regional and Sex-Related Differences
Śmiłowska, K., Pietrzykowski, T., Owczarek, A. J., Dorsey, E. R., Bloem, B. R., & van Wamelen, D. J. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-230291 · Cited by 9
“Other estimates put the PD prevalence around 0.3% of the entire population and around 1% of the population above 60 years [18, 19].”
BackgroundInfluentialChen, S., & Lin, C.-L. (2024) · IEEE Open Journal of Antennas and Propagation · doi:10.1109/ojap.2024.3393117 · Cited by 9
Baek, S. H., Park, S., Yu, M., Kim, J. E., Park, S. H., Han, K., Kim, Y. C., Kim, D. K., Joo, K. W., Kim, Y. S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-90130-9 · Cited by 9
Cosentino, G., Todisco, M., & Blandini, F. (2022) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819410-2.00010-2 · Cited by 9
Kuo, C.-W., Chang, M., Chou, M.-Y., Pan, C., Peng, C., Tseng, H.-C., Jen, T.-Y., He, X., Liu, H.-H., Nguyen, T. X. D., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.848380 · Cited by 9
Quality of life assessment after total knee arthroplasty in patients with Parkinson’s disease
Zong, Y., Hao, C., Zhang, Y., & Wu, S. (2022) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-022-05176-1 · Cited by 10
Doğan, M., Eröz, R., Tecellioğlu, M., Gezdirici, A., Çevik, B., & Barış, İ. (2022) · Current Alzheimer Research · doi:10.2174/1567205019666220414101251 · Cited by 12
Archibald, N. K., & Burn, D. J. (2008) · Medicine · doi:10.1016/j.mpmed.2008.09.004 · Cited by 9
Jeong, S. H., Kim, S. H., Lee, D. W., Park, E., & Jang, S. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03990-4 · Cited by 9
Analyzing the bibliometrics of brain-gut axis and Parkinson’s disease
Chen, L., Chen, J., Wu, M., Yan, P., & Zhou, X. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1343303 · Cited by 9
Nutrition and Gastrointestinal Health as Modulators of Parkinson’s Disease
Rasmussen, H. E., Piazza, B., Forsyth, C. B., & Keshavarzian, A. (2014) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-06151-1_11 · Cited by 9
Miri, R., Firuzi, O., Razzaghi‐Asl, N., Javidnia, K., & Edraki, N. (2014) · Archives of Pharmacal Research · doi:10.1007/s12272-014-0401-x · Cited by 9
“Alzheimer disease (AD) is a common form of mental dementia clinically recognized by progressive decline in memory and cognition (Nussbaum and Ellis 2003).”
BackgroundXu, J., Ji, F., Cao, X., Ma, J., Ohizumi, Y., Lee, D., & Guo, Y. (2016) · Journal of Functional Foods · doi:10.1016/j.jff.2016.01.012 · Cited by 9
Toll-Like Receptor Signaling in Alzheimer?s Disease Progression
Downer, E. J. (2012) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.s10-006 · Cited by 9
Spodzieja, M., Kalejta, K., Kołodziejczyk, A. S., Maszota‐Zieleniak, M., Rodziewicz‐Motowidło, S., Żmudzińska, W., & Czaplewska, P. (2016) · Journal of Molecular Recognition · doi:10.1002/jmr.2581 · Cited by 9
Chinese medicine for idiopathic Parkinson’s disease: A meta analysis of randomized controlled trials
Wei, W., Chen, H., Fan, W., Ye, S., Xu, Y., & Cai, J. (2016) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-016-2618-7 · Cited by 9
Fang, L., Tang, B.-S., Fan, K., Wan, C.-M., Yan, X., & Guo, J. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.04.042 · Cited by 10
Rashedinia, M., Mojarad, M., Khodaei, F., Sahragard, A., Khoshnoud, M. J., & Zarshenas, M. M. (2021) · BioMed Research International · doi:10.1155/2021/5577594 · Cited by 10
Identifying Disease Signatures in the Spinocerebellar Ataxia Type 1 Mouse Cortex
Luttik, K. P., Olmos, V. B., Owens, A., Khan, A., Yun, J., Driessen, T. M., & Lim, J. (2022) · Cells · doi:10.3390/cells11172632 · Cited by 9
Lennert, B., Bibeau, W. S., Farrelly, E., Sacco, P., & Schoor, T. (2012) · PubMed · Cited by 9
Benign tremulous Parkinsonism: a unique entity or another facet of Parkinson’s disease?
Deeb, W., Hu, W., Almeida, L., Patterson, A., Martínez-Ramírez, D., & Shukla, A. W. (2016) · Translational Neurodegeneration · doi:10.1186/s40035-016-0057-1 · Cited by 9
Powell, D. W., Blackmore, S. E., Puppa, M., Lester, D. B., Murray, N. G., Reed-Jones, R. J., & Xia, R. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.05.010 · Cited by 9
Imaging as Biomarker for Decision-Making in Drug Development
Hargreaves, R. J., & Wagner, J. A. (2006) · CRC Press eBooks · doi:10.3109/9781420004526-5 · Cited by 10
Muscarà, C., Gugliandolo, A., Mazzon, E., & Calì, G. (2025) · Antioxidants · doi:10.3390/antiox14070818 · Cited by 9
Ghosh, R., Dutta, S., Ganguly, A., Samanta, S., & Rajak, P. (2025) · Pesticide Biochemistry and Physiology · doi:10.1016/j.pestbp.2025.106838 · Cited by 9
McManus, K., McGrath, D., Greene, B. R., Lennon, O. C., McMahon, L., & Caulfield, B. M. (2019) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc.2019.8857162 · Cited by 8
“Parkinson’s disease (PD) is a neurodegenerative disorder with a prevalence rate of approximately 1% among persons 60 years of age or older [1].”
BackgroundMcKay, M. A., Gorai, S., Paidi, R. K., Mondal, S., & Pahan, K. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230179 · Cited by 8
“On the other hand, being the most common form of dementia, AD is clinically characterized by progressive impairment in memory, judgment, decision making, and language usage [4].”
BackgroundInference of dependency knowledge graph for Electronic Health Records
Xu, Z., Gan, Z., Zhou, D., Shen, S., Lu, J., & Cai, T. (2025) · Journal of the Royal Statistical Society Series B (Statistical Methodology) · doi:10.1093/jrsssb/qkaf061 · Cited by 8
Sato, H., Kato, T., & Arawaka, S. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8858-7 · Cited by 9
Bordone, M. C., & Barbosa‐Morais, N. L. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.607215 · Cited by 11
“The major risk factor for those disorders is aging (Niccoli and Partridge, 2012), the age of onset of both AD or PD being around 65 years old (Nussbaum and Ellis, 2003).”
BackgroundKhatami, S. G., Domingo‐Fernándéz, D., Mubeen, S., Hoyt, C. T., Robinson, C., Karki, R., Iyappan, A., Kodamullil, A. T., & Hofmann‐Apitius, M. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201397 · Cited by 9
“genetic, pathological, and clinical overlap with AD [27].”
BackgroundNguyen, V. P., Collins, A. E., Hickey, J. P., Pfeifer, J. A., & Kalisch, B. E. (2023) · Brain Sciences · doi:10.3390/brainsci13010153 · Cited by 9
“Alzheimer’s disease (AD) and Parkinson’s disease (PD) are chronic neurodegenerative disorders that involve the loss of neurons and synapses and the deposition of aberrant proteins [1,2].”
BackgroundInfluentialStriatal serotonin transporter gain-of-function in L-DOPA-treated, hemi-parkinsonian rats
Mazza, M. C., Centner, A., Werner, D. F., & Bishop, C. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148381 · Cited by 8
Prospective Role of PAK6 and 14-3-3γ as Biomarkers for Parkinson’s Disease
Giusto, E., Maistrello, L., Iannotta, L., Giusti, V., Iovino, L., Bandopadhyay, R., Antonini, A., Bubacco, L., Barresi, R., Plotegher, N., et al. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-230402 · Cited by 9
Parkinson's disease: treatment
(2000) · Pharmaceutical journal/The pharmaceutical journal · doi:10.1211/pj.2000.20000925 · Cited by 8
Genetic analysis of FGF20 in Chinese patients with Parkinson’s disease
Sun, X., Wang, L., Cheng, L., Li, N., Lu, Z., Li, J., & Peng, R. (2017) · Neurological Sciences · doi:10.1007/s10072-017-2868-y · Cited by 8
Nishijima, H., Kimura, T., Mori, F., Wakabayashi, K., Kinoshita, I., Nakamura, T., Kon, T., Suzuki, C., & Tomiyama, M. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.650350 · Cited by 8
Ageing, Metabolic Dysfunction, and the Therapeutic Role of Antioxidants
Santos, A. L., & Sinha, S. (2023) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-26576-1_15 · Cited by 8
Five-year fracture risk estimation in patients with Parkinson's disease
Pouwels, S., Bazelier, M. T., de Boer, A., Weber, W. E. J., Neef, C., Cooper, C. C., & de Vries, F. (2013) · Bone · doi:10.1016/j.bone.2013.06.018 · Cited by 8
“Parkinson's disease (PD) is a movement disorder, which has a prevalence of about 1% in people over 60 years of age [1].”
BackgroundLegacy of the American eugenics movement: implications for primary care
Stehney, M. A. (2004) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2004.04.013 · Cited by 8
“The spectrum of ‘‘genetic’’ health care decisions likely to be encountered in primary care ranges from deciding to test for iron overload in the sibling of a person with hemochromatosis (which may allow early diagnosis and prevention of serious morbidity), through the decision whether to screen for risk of Down syndro…”
Background
Metadata
- Authors
- Nussbaum, R. L., & Ellis, C. E.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Nussbaum, Robert L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-04-03
- Volume
- 348
- Issue
- 14
- Pages
- 1356-1364
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149522871
- Cited by
- 1,351
- References
- 107
- Citations by year
- 2026: 25 · 2025: 55 · 2024: 75 · 2023: 74 · 2022: 80 · 2021: 82 · 2020: 80 · 2019: 83 · 2018: 74 · 2017: 74 · 2016: 63 · 2015: 54 · 2014: 65 · 2013: 46 · 2012: 66
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- Alzheimer's disease, Parkinson's disease, genetic susceptibility, inherited neurodegenerative disorders
- MeSH terms
- Alzheimer Disease, Amino Acid Sequence, Apolipoproteins E, Humans, Molecular Sequence Data, Nerve Tissue Proteins, Substantia Nigra, Prevalence, Amyloid beta-Protein Precursor, Lewy Bodies, Mutation, Missense, Parkinsonian Disorders, Synucleins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.